These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21532215)

  • 1. Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer.
    Yao S; Xu B; Li Q; Zhang P; Yuan P; Wang J; Ma F; Fan Y
    Endocr J; 2011; 58(6):509-16. PubMed ID: 21532215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy.
    Liu X; Qu H; Cao W; Wang Y; Ma Z; Li F; Wang H
    Endocr J; 2013; 60(6):819-28. PubMed ID: 23714650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Goserelin plus anastrozole in the treatment of premenopausal patients with metastatic breast cancer].
    Yao SY; Xu BH; Li Q; Zhang P; Wang JY; Yuan P; Ma F; Cai RG
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(8):526-8. PubMed ID: 20367963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
    Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
    J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
    Forward DP; Cheung KL; Jackson L; Robertson JF
    Br J Cancer; 2004 Feb; 90(3):590-4. PubMed ID: 14760369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
    Carlson RW; Theriault R; Schurman CM; Rivera E; Chung CT; Phan SC; Arun B; Dice K; Chiv VY; Green M; Valero V
    J Clin Oncol; 2010 Sep; 28(25):3917-21. PubMed ID: 20679610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer.
    Wang J; Xu B; Yuan P; Ma F; Li Q; Zhang P; Cai R; Fan Y; Luo Y; Li Q
    Medicine (Baltimore); 2015 Jul; 94(26):e1006. PubMed ID: 26131799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
    Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
    Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
    Nishimura R; Anan K; Yamamoto Y; Higaki K; Tanaka M; Shibuta K; Sagara Y; Ohno S; Tsuyuki S; Mase T; Teramukai S
    Oncol Rep; 2013 May; 29(5):1707-13. PubMed ID: 23446822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
    Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
    Cheung KL; Agrawal A; Folkerd E; Dowsett M; Robertson JF; Winterbottom L
    Eur J Cancer; 2010 Nov; 46(16):2936-42. PubMed ID: 20832294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
    Riemsma R; Forbes CA; Amonkar MM; Lykopoulos K; Diaz JR; Kleijnen J; Rea DW
    Curr Med Res Opin; 2012 Aug; 28(8):1263-79. PubMed ID: 22738819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
    Shankar A; Roy S; Rath GK; Julka PK; Kamal VK; Malik A; Patil J; Jeyaraj PA; Mahajan MK
    Asian Pac J Cancer Prev; 2015; 16(15):6359-64. PubMed ID: 26434843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
    Di Lauro L; Vici P; Del Medico P; Laudadio L; Tomao S; Giannarelli D; Pizzuti L; Sergi D; Barba M; Maugeri-Saccà M
    Breast Cancer Res Treat; 2013 Aug; 141(1):119-23. PubMed ID: 23982884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
    Kim JY; Im SA; Jung KH; Ro J; Sohn J; Kim JH; Park YH; Kim TY; Kim SB; Lee KS; Kim GM; Kim SH; Kim S; Ahn JS; Lee KH; Ahn JH; Park IH; Im YH;
    Eur J Cancer; 2018 Nov; 103():127-136. PubMed ID: 30223226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
    Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
    Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
    Beom SH; Oh J; Kim TY; Lee KH; Yang Y; Suh KJ; Moon HG; Han SW; Oh DY; Han W; Kim TY; Noh DY; Im SA
    Cancer Res Treat; 2017 Apr; 49(2):454-463. PubMed ID: 27554482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).
    Dickler MN; Barry WT; Cirrincione CT; Ellis MJ; Moynahan ME; Innocenti F; Hurria A; Rugo HS; Lake DE; Hahn O; Schneider BP; Tripathy D; Carey LA; Winer EP; Hudis CA
    J Clin Oncol; 2016 Aug; 34(22):2602-9. PubMed ID: 27138575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.